WAVE Life Sciences Ltd. (NASDAQ:WVE) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Analysts have set a one year consensus price objective of $42.33 for the company and are anticipating that the company will post ($0.69) earnings per share for the current quarter, according to Zacks. Zacks has also assigned WAVE Life Sciences an industry rank of 68 out of 265 based on the ratings given to related companies.

Several equities research analysts have weighed in on the company. Zacks Investment Research cut WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 15th. Jefferies Group boosted their price objective on WAVE Life Sciences from $28.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, November 14th. Leerink Swann reissued an “outperform” rating and set a $45.00 price objective on shares of WAVE Life Sciences in a research note on Thursday, November 10th. Finally, JMP Securities reissued a “buy” rating on shares of WAVE Life Sciences in a research note on Thursday, November 10th.

WAVE Life Sciences (NASDAQ:WVE) opened at 28.05 on Monday. WAVE Life Sciences has a 52-week low of $8.95 and a 52-week high of $40.15. The company’s market cap is $658.47 million. The company’s 50-day moving average price is $32.17 and its 200-day moving average price is $27.57.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate WAVE Life Sciences Ltd. (WVE) to Post ($0.69) Earnings Per Share” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of US and international trademark and copyright laws. The original version of this report can be viewed at http://www.watchlistnews.com/brokerages-anticipate-wave-life-sciences-ltd-wve-to-post-0-69-earnings-per-share/1061135.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN acquired a new position in shares of WAVE Life Sciences during the third quarter valued at about $136,000. BlackRock Advisors LLC raised its position in shares of WAVE Life Sciences by 67.6% in the third quarter. BlackRock Advisors LLC now owns 4,264 shares of the company’s stock valued at $138,000 after buying an additional 1,720 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of WAVE Life Sciences during the third quarter valued at about $176,000. Strs Ohio acquired a new position in shares of WAVE Life Sciences during the third quarter valued at about $194,000. Finally, Lesa Sroufe & Co acquired a new position in shares of WAVE Life Sciences during the third quarter valued at about $209,000. Institutional investors and hedge funds own 59.91% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Get a free copy of the Zacks research report on WAVE Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.